オピストルキス症治療の世界市場

オピストルキス症治療の世界市場は2030年までに5億460万米ドルに達する見込み

2024年に3億8,950万米ドルと推定されるオピストルキス症治療の世界市場は、分析期間2024～2030年にCAGR 4.4%で成長し、2030年には5億460万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである投薬タイプは、CAGR 3.6％を記録し、分析期間終了時には3億2,320万米ドルに達すると予測されます。手術タイプ」の成長率は、分析期間を通じてCAGR 6.0％と推定されます。

米国市場は1億610万米ドルと推定、中国はCAGR6.9％で成長予測

米国のオピストルキス症治療市場は2024年に1億610万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9,760万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と4.4%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

世界のオピストルキス症治療情勢- 主要動向と促進要因のまとめ

オピストルキス症はなぜ公衆衛生上の問題なのか、何が治療の必要性を引き起こすのか？

オピストルキス症は、主にOpisthorchis viverriniとOpisthorchis felineusという肝蛭によって引き起こされる寄生虫感染症であり、淡水魚の生食や加熱不足によって感染します。この病気は東南アジア、東欧、シベリアの一部で流行しています。慢性感染は何十年も続くことがあり、肝臓、胆嚢、胆管を損傷します。時間の経過とともに、胆管炎、胆嚢炎、胆管がんなどの重篤な合併症を引き起こす可能性があります。

流行地域では伝統的な生魚料理が広く消費されているため、感染が持続します。感染者は何年も無症状のままであることがあり、診断の遅れや治療の遅れの一因となっています。ひとたび症状が現れると、腹痛、疲労、消化不良、肝胆道系の異常などが見られます。肝フルークに関連する合併症に対するヘルスケアの認識が高まり、サーベイランス・プログラムが充実してきたことで、医療従事者は早期介入戦略を追求するようになりました。正確な診断は、通常、便の顕微鏡検査または高度な抗原検出法に基づいて行われ、時宜を得た治療を行うために極めて重要です。

どのような治療法があり、臨床でどの程度有効か？

オピストフォルキア症に対する主な薬理学的治療は、プラジカンテルという広域抗寄生虫薬を短期間投与することです。プラジカンテルは寄生虫のカルシウムイオンバランスを破壊し、麻痺と死亡を引き起こします。治療は一般的に有効で、治癒率も高く、忍容性も良好です。環境によってはアルベンダゾールが代替薬として考慮されるが、一般的にオピストホルキス種に対する効果は低いです。寄生虫負荷が高い場合や再感染した場合は、繰り返し治療が必要になることがあります。

胆道の炎症や線維化を伴う進行例では、対症療法が必要な場合があります。支持療法には、鎮痙薬、肝保護薬、胆汁流調節薬が含まれます。胆石や胆管閉塞などの合併症を伴う症例では、外科的介入が必要となることもあります。肝胆道がんのリスクが高いため、感染を繰り返す患者には長期間の経過観察が推奨されます。集団薬剤投与キャンペーンなどの公衆衛生介入と抗寄生虫治療を統合することで、流行地域社会における感染症の流行が減少することが示されています。

どのような予防・全身対策が治療戦略を形成しているのか？

オピストルキス症制圧への取り組みは、治療介入と公衆衛生教育および食品安全キャンペーンを組み合わせるようになってきています。安全な食品調理法の普及、特に生魚や発酵した淡水魚の摂取を控えることは、感染を減らす上で重要な役割を担っています。いくつかの流行国では、地域ぐるみの駆虫プログラムが実施されており、学校での検診や国家的な防疫戦略の支援を受けています。

水の衛生環境、健康教育、診断へのアクセスの改善により、治療効果はさらに高まっています。特に小児や社会的弱者に対しては、安全性を向上させたワクチンや、より選択性の高い駆虫薬の研究が進められています。デジタルツールや地理空間マッピングに支えられたサーベイランスシステムの強化により、標的を絞った介入とアウトブレイクの封じ込めが可能になっています。保健省と国際保健機関とのパートナーシップは、長期的な疾病管理目標に貢献しています。

オピストルキス症治療市場の成長を促進する要因とは？

オピストルキス症治療市場の成長は、いくつかの要因によってもたらされます。アジアと東欧の一部で蔓延が続いており、診断・治療サービスへの需要が維持されています。慢性感染症に関連した肝胆膵疾患の発生率の増加により、早期の医療介入が求められています。プラジカンテルなどの有効で安価な駆虫薬が入手可能なため、集団治療への取り組みが促進されています。公衆衛生のインフラと疾病監視プログラムの拡大により、農村部や十分な医療が行き届いていない地域でも医療への幅広いアクセスが可能になりつつあります。食品媒介寄生虫のリスクに対する認識が高まり、国家的な疾病管理の枠組みに治療が組み込まれていることが、一貫した需要を支えています。これらの要因が相まって、オピストホルキアの世界の管理において、タイムリーでアクセスしやすい地域レベルの治療戦略の重要性が強化されています。

セグメント

タイプ（投薬タイプ,手術タイプ）;診断手技（胆管造影診断手技MRI診断手技、超音波診断手技CTスキャン診断手技、その他の診断手技）;症状（黄疸症状、下痢症状、発熱症状、脾腫症状、体重減少症状、頻脈症状、その他の症状）;エンドユーザー（病院・診療所エンドユーザー,外来手術センターエンドユーザー,その他のエンドユーザー）

調査対象企業の例

• AbbVie
• Astellas Pharma
• Bayer AG
• Boehringer Ingelheim
• Cipla Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline plc
• Hubei Zhongjia-Chem Pharmaceutical
• Johnson & Johnson
• Merck KGaA
• Merck Sharp & Dohme（MSD）
• Mankind Pharma
• Novartis AG
• Pfizer Inc.
• Sanofi
• Shin Poong Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Opisthorchiasis Treatment Market to Reach US$504.6 Million by 2030

The global market for Opisthorchiasis Treatment estimated at US$389.5 Million in the year 2024, is expected to reach US$504.6 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Medications Type, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$323.2 Million by the end of the analysis period. Growth in the Surgery Type segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$106.1 Million While China is Forecast to Grow at 6.9% CAGR

The Opisthorchiasis Treatment market in the U.S. is estimated at US$106.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$97.6 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Opisthorchiasis Treatment Landscape - Key Trends & Drivers Summarized

Why Is Opisthorchiasis a Public Health Concern and What Triggers the Need for Treatment?

Opisthorchiasis is a parasitic infection caused by liver flukes, primarily Opisthorchis viverrini and Opisthorchis felineus, acquired through consumption of raw or undercooked freshwater fish. The disease is endemic in regions of Southeast Asia, Eastern Europe, and parts of Siberia. Chronic infections can persist for decades, damaging the liver, gallbladder, and bile ducts. Over time, they can lead to severe complications such as cholangitis, cholecystitis, and a heightened risk of cholangiocarcinoma.

Widespread consumption of traditional raw fish dishes in endemic areas sustains transmission. Infected individuals may remain asymptomatic for years, contributing to underdiagnosis and delayed treatment. Once symptoms emerge, they may include abdominal pain, fatigue, indigestion, and hepatobiliary abnormalities. Increasing awareness of liver fluke-related complications and broader surveillance programs are prompting healthcare providers to pursue early intervention strategies. Accurate diagnosis, typically based on stool microscopy or advanced antigen detection methods, is critical for timely treatment.

What Therapies Are Available and How Effective Are They in Clinical Practice?

The primary pharmacological treatment for opisthorchiasis is praziquantel, a broad-spectrum antiparasitic agent administered in short-course regimens. It acts by disrupting calcium ion balance in the parasites, causing paralysis and death. Treatment is generally effective, with high cure rates and good tolerability. In some settings, albendazole is considered as an alternative, though it is typically less effective against Opisthorchis species. Repeat treatment may be required in cases of high parasite burden or reinfection.

Symptomatic management may be necessary in advanced cases involving biliary tract inflammation or fibrosis. Supportive therapies may include antispasmodics, hepatoprotective agents, and bile flow regulators. Surgical interventions may be required in cases involving complications such as gallstones or bile duct obstruction. Long-term follow-up is recommended for patients with repeated infections due to elevated risk of hepatobiliary cancers. Integration of antiparasitic treatment with public health interventions, such as mass drug administration campaigns, has been shown to reduce infection prevalence in endemic communities.

What Preventive and Systemic Measures Are Shaping Treatment Strategies?

Efforts to control opisthorchiasis are increasingly combining therapeutic intervention with public health education and food safety campaigns. Promotion of safe food preparation practices, especially discouraging consumption of raw or fermented freshwater fish, plays a critical role in reducing transmission. Community-wide deworming programs have been implemented in several endemic countries, supported by school-based screening and national control strategies.

Improvements in water sanitation, health education, and access to diagnostics are reinforcing treatment effectiveness. Research is ongoing into potential vaccines and more selective anthelmintic agents with improved safety profiles, especially for children and vulnerable populations. Enhanced surveillance systems, supported by digital tools and geospatial mapping, are enabling targeted intervention and outbreak containment. Partnerships between health ministries and international health organizations are contributing to long-term disease control objectives.

What Factors Are Driving Growth in the Opisthorchiasis Treatment Market?

Growth in the opisthorchiasis treatment market is driven by several factors. Persistent endemicity in parts of Asia and Eastern Europe is maintaining demand for diagnostic and therapeutic services. Increasing incidence of hepatobiliary diseases linked to chronic infection is prompting earlier medical intervention. Availability of effective, affordable anthelmintic drugs such as praziquantel is facilitating mass treatment initiatives. Expansion of public health infrastructure and disease monitoring programs is enabling broader access to care in rural and underserved areas. Rising awareness of foodborne parasitic risks and integration of treatment into national disease control frameworks are supporting consistent demand. These factors are collectively reinforcing the importance of timely, accessible, and community-level treatment strategies in managing opisthorchiasis globally.

SCOPE OF STUDY:

The report analyzes the Opisthorchiasis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Medications Type, Surgery Type); Diagnostic Procedure (Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure, Other Diagnostic Procedures); Symptom (Jaundice Symptom, Diarrhea Symptom, Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie
• Astellas Pharma
• Bayer AG
• Boehringer Ingelheim
• Cipla Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline plc
• Hubei Zhongjia-Chem Pharmaceutical
• Johnson & Johnson
• Merck KGaA
• Merck Sharp & Dohme (MSD)
• Mankind Pharma
• Novartis AG
• Pfizer Inc.
• Sanofi
• Shin Poong Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Opisthorchiasis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Foodborne Parasitic Infections in Southeast Asia Drives Demand for Opisthorchiasis Treatment Protocols
  • Expansion of Public Health Surveillance Programs Strengthens Early Detection and Community-Based Case Management
  • Increased Availability and Distribution of Antiparasitic Drugs Like Praziquantel Support Scalable Treatment Coverage
  • Growth in Awareness Campaigns on Raw Fish Consumption Risks Spurs Preventive Screening and Early Therapeutic Intervention
  • Integration of Diagnosis and Treatment Through Primary Care Networks Enhances Reach in Endemic Rural Areas
  • Support from Global Health Organizations for Helminthic Disease Control Accelerates Drug Access and Treatment Infrastructure
  • Advancements in Molecular Diagnostics and ELISA-Based Tests Improve Detection of Low-Intensity and Asymptomatic Infections
  • Development of Drug Resistance Monitoring Systems Strengthens Sustainability of Current First-Line Therapies
  • Expansion of School-Based Deworming Programs Includes Opportunistic Screening for Liver Fluke Infections
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Opisthorchiasis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Opisthorchiasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Opisthorchiasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Medications Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Medications Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Medications Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Surgery Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Surgery Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Surgery Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Fever Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Fever Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Fever Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Splenomegaly Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Splenomegaly Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Splenomegaly Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Weight loss Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Weight loss Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Weight loss Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Tachycardia Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Tachycardia Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Tachycardia Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Symptoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Jaundice Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Jaundice Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Jaundice Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diarrhea Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diarrhea Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Diarrhea Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Cholangiography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Cholangiography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Cholangiography Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for MRI Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for MRI Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for MRI Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Ultrasonography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Ultrasonography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Ultrasonography Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for CT scan Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for CT scan Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for CT scan Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other Diagnostic Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other Diagnostic Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Other Diagnostic Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: USA 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Canada 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• JAPAN
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Japan 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• CHINA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 92: China Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: China 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• EUROPE
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Opisthorchiasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Opisthorchiasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Europe 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• FRANCE
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 119: France Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: France 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• GERMANY
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Germany 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Italy 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 155: UK Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: UK 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Spain 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Russia 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Opisthorchiasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Australia 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• INDIA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 230: India Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: India 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: South Korea 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Opisthorchiasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Opisthorchiasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Latin America 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Argentina 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Brazil 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Mexico 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Opisthorchiasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Opisthorchiasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 343: Middle East 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 355: Iran 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 367: Israel 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 391: UAE 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030
• AFRICA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Opisthorchiasis Treatment by Type - Medications Type and Surgery Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Opisthorchiasis Treatment by Type - Percentage Breakdown of Value Sales for Medications Type and Surgery Type for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Opisthorchiasis Treatment by Symptom - Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Opisthorchiasis Treatment by Symptom - Percentage Breakdown of Value Sales for Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms, Jaundice Symptom and Diarrhea Symptom for the Years 2014, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Opisthorchiasis Treatment by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Opisthorchiasis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Opisthorchiasis Treatment by Diagnostic Procedure - Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 415: Africa 16-Year Perspective for Opisthorchiasis Treatment by Diagnostic Procedure - Percentage Breakdown of Value Sales for Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure and Other Diagnostic Procedures for the Years 2014, 2025 & 2030

IV. COMPETITION